pocketful logo light
pocketful logo light
Mankind Pharma Ltd logo

Mankind Pharma Ltd

NSE: MANKIND BSE: 543904

2391

(1.43%)

Mon, 15 Jun 2026, 07:42 am

Mankind Pharma Share Price Live Chart

1 Day

(1.43%)

No Result Found

Summary

  • Market Cap (in Cr)

    98179.49

  • Net Profit (in Cr)

    2011.12

  • P/B

    6.98

  • Sector P/E

    33.76

  • P/E

    50.22

  • EV/EBITDA

    30.20

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    14.83

  • ROCE

    16.04

  • Debt/Equity

    0.37

  • EPS (TTM)

    48.69

  • Dividend Yield

    0

  • Book Value

    394.77

  • Interest Cover

    6.08

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters72.6672.6672.6772.6872.70
FII10.2411.3412.8413.0712.92
DII14.4613.2511.9211.5011.48
Public2.642.752.572.752.90
Government0000.000.00

Read More

Technical Analysis

RSI

53.35

MACD

10.10

50 DMA

2299.88

200 DMA

2281.91

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic3215.932816.932596.272417.932197.272018.931619.93
Fibonacci2816.932664.522570.352417.932265.522171.352018.93
Camarilla2485.322448.752412.172417.932339.032302.452265.88

Pivots Level: Classic

R3

+798

3215.93

R2

+399

2816.93

R1

+178.33

2596.27

2417.93
2417.93
Pivot Point
LTP: 2392.50

S1

-220.67

2197.27

S2

-399

2018.93

S3

-798

1619.93

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    2379.18

  • 20-EMA

    2378.96

  • 30-EMA

    2362.67

  • 50-EMA

    2322.38

  • 100-EMA

    2275.58

  • 200-EMA

    2285.68

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
19 May 2026board-meetingsAccounts, Quarterly Results
03 Feb 2026board-meetingsQuarterly Results
06 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
31 Jul 2025dividend₹1.00 Dividend /Share08 Aug 2025
08 Jul 2025dividendInterim Dividend - Rs. - 108 Aug 2025
03 Jul 2025agm
18 Jul 2024agm
24 Aug 2023agm

Read More

Peer Comparison

Mankind Pharma Ltd logo

Mankind Pharma Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Mankind Pharma Ltd About

Mankind Pharma is principally engaged in the manufacturing and trading of pharmaceuticals and health care products. Pursuant to scheme of amalgamation, the Company has three manufacturing facilities at Paonta Sahib in the state of Himachal Pradesh, one manufacturing facility in state of Sikkim, two manufacturing facilities in state of Rajasthan, one manufacturing facility in state of Andhra Pradesh, three in-house research and development centres in the state of Haryana and one research and development centre in the state of Maharashtra to carry out research in pharmaceutical products.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1991

Headquarters

CEO

RAMESH CHAND JUNEJA

Employees

Contact

Website icon

Website

http://www.mankindpharma.com

Email icon

Email

investors@mankindpharma.com

Phone icon

Phone

91-11-47476600

Location icon

Location

208 Okhla Industrial Estate, Phase-III, New Delhi, New Delhi, 110020

Read More

Mankind Pharma Ltd Company History

YearHistory
2020
  • Incorporated Lifestar Pharmaceuticals Private Limited in Nepal
  • Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of Cilaheart tablets and Statpure tablets
  • Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of Zukanorm tablets
2021
  • Incorporated Mankind Pharma FZ-LLC in Dubai, UAE
  • Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of Mlife tablets
  • Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of Trugaba-NT tablets and Prebris-MNT tablets
2022
  • Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited
  • Entered into transplant segment with the launch of Pangraf Capsules and Mycept tablets amongst others
  • Entered into oncology segment with the launch of Pacliall injection amongst others
  • Acquired the brands Daffy and Combihale from Dr. Reddy’s Laboratories
  • Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited.
2023
  • Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence.
  • Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API.
  • Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution.
2024
  • Mankind Pharma Completes Landmark Acquisition of BSV.
  • Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab.
  • Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups.
  • Mankind Pharma Product Healthok has joined hands with Bikanervala.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GOLDMAN SACHS (SINGAPORE) PTE - ODIblockSell55000243014 Oct 2025
GOLDMAN SACHS BANK EUROPE SE - ODIblockBuy55000243014 Oct 2025
GOLDMAN SACHS (SINGAPORE) PTE - ODIblockSell42245244013 Oct 2025
GOLDMAN SACHS BANK EUROPE SE - ODIblockBuy42245244013 Oct 2025
GOLDMAN SACHS (SINGAPORE) PTE.- ODIblockBuy550002434.109 May 2025
COPTHALL MAURITIUS INVESTMENT LIMITEDblockSell550002434.109 May 2025
SOCIETE GENERALEblockBuy120078208210 Jul 2024
AURIGIN MASTER FUND LIMITEDblockBuy48032208210 Jul 2024
CITIGROUP GLOBAL MARKETS MAURITIUS PRIVATE LIMITED (ODI)blockBuy48032208210 Jul 2024
CITIGROUP GLOBAL MARKETS MAURITIUS PVT LTDblockBuy96063208210 Jul 2024

Read More

Mankind Pharma Ltd News

Mankind Pharma confirms no encumbrance on shares

Promoters of Mankind Pharma confirmed no encumbrance on shares for FY26 under SEBI regulations.

10 Jun 2026

companies

Mankind Pharma appoints Nilesh Kulkarni as HR head

Mankind Pharma Limited has appointed Mr. Nilesh Kulkarni as the Head of Human Resource Functions and designated him as a Senior Management Personnel effective June 8, 2026. This follows an internal organizational restructuring.

08 Jun 2026

companies

Jefferies Maintains Buy on Mankind Pharma, TP ₹3,000

Jefferies reiterates Buy rating on Mankind Pharma with a target price of ₹3,000, backed by double-digit India growth, high-teens export expansion, and R&D upside.

03 Jun 2026

investment-ideas

Mankind Pharma acquires 100% of Upakarma Ayurveda

Mankind Pharma's subsidiary acquired the remaining 10% stake in Upakarma Ayurveda for ₹75 Lakhs to streamline operations.

02 Jun 2026

companies

Mankind Pharma Block Trade: ₹26.93 Cr on NSE

Mankind Pharma sees a block trade of ~1,07,595 shares on NSE at ₹2502.50 per share, aggregating to ₹26.93 crores.

22 May 2026

equity-markets

Read More

Open Your Free Demat Account

Enter your phone number